RetatrutideEvidence & Dosage
Triple agonist (GLP-1/GIP/glucagon) — impressive weight data in phase III.
Evidence at a glance
- Total studies
- 322
- With abstract
- 50
- Meta / Systematic / RCT
- 9
- Highly cited
- 50
- Publication years
- 2000–2026
Retatrutide in the context of Peptides
This topic is part of our "Peptides" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.
Go to PeptidesTop studies on Retatrutide
Ranked by influential-citation count and publication year.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet (London, England)2005200 influential citations<h4>Background</h4>In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on…
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
The New England journal of medicine2005200 influential citations<h4>Background</h4>Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined…
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Hypertension (Dallas, Tex. : 1979)2004200 influential citationsThe metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome…
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (London, England)2023n=281200 influential citationsBACKGROUND According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent…
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine2024200 influential citationsRetatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8…
The role of incretins in glucose homeostasis and diabetes treatment.
Pharmacological reviews2008166 influential citationsIncretins are gut hormones that are secreted from enteroendocrine cells into the blood within minutes after eating. One of their many physiological roles is to regulate the amount of insulin that is secreted after eating. In this manner,…
Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
BMJ (Clinical research ed.)2007n=6,365151 influential citations<h4>Objective</h4>To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.<h4>Design</h4>Updated meta-analysis of randomised trials.<h4>Data sources</h4>Medline, Embase, the Cochrane…
Incretin-based therapies for type 2 diabetes mellitus.
Nature reviews. Endocrinology2009142 influential citationsIncretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents regulate glucose metabolism through multiple mechanisms,…
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Diabetes, obesity & metabolism2016135 influential citationsOver the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin system, specifically targeting the receptor for the incretin…
Anti-Obesity Drugs: A Review about Their Effects and Safety.
Diabetes & metabolism journal2012n=15,686131 influential citationsThe current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years,…
More topics in Peptides
Peptides Overview
Peptides, BPC-157, TB-500, safety and the state of the evidence.
Administration Routes
Subcutaneous, intramuscular, nasal, oral, topical — bioavailability and safety.
Autoimmunity Risk
Immune modulation can both promote tolerance and tip into dysregulation.
BPC-157
Peptide for tissue regeneration, healing, and athletic recovery.
Cerebrolysin
A pig-brain peptide mix, stroke studies, not approved in Germany.
CJC-1295
GHRH analog, half‑life variants and pulse patterns.
Dihexa
Angiotensin derivative, cognitive/neuroplasticity signals in animal models.
GHK-Cu
Copper peptide for skin health, anti-aging, and wound healing.
GHRP-2
GH releaser, older generation, appetite stimulation as a side effect.
GHRP-6
GH releaser with a strong appetite component.
GLP-1 Rebound
Weight regain after stopping without lifestyle anchors.
GLP-1 Side Effects
Nausea, gastric emptying, muscle loss, pancreatitis risk.
Hexarelin
GH releaser, fast tolerance build-up, cardiac signals.
IGF-1 LR3
Modified IGF-1 with a long half-life — hypertrophy, the cancer-risk debate.
Immune Modulation
Automatisch via Trend Scout entdeckt. Supplements targeting inflammation and immune resilience remain a central research area.. PubMed: 11956 Ergebnisse.
Injection Safety
Sterile technique, bacteriostatic water, skin disinfection — a medical topic.
Ipamorelin
Selective GH releaser, cortisol‑sparing, and stack combinations.
KPV
An alpha-MSH fragment — anti-inflammatory, gut, skin, early research.
Liraglutide
First-generation GLP-1 for diabetes/obesity — daily, smaller effect size.
LL-37
Antimicrobial peptide, wound healing, immune modulation, early research.
Related topics from other worlds
Blood Pressure Tracking
Home measurement, 24h monitoring, white-coat hypertension.
HbA1c
A 3-month average of blood sugar, diabetes risk, a longevity marker.
Mood Tracking
Daily mood logging, correlations with sleep/exercise/nutrition.
Adrenal Glands
Cortisol, DHEA, adrenaline — the stress response and daily rhythm.
DHEA
DHEA as a precursor hormone for hormonal balance and vitality.
GLP-1
Glucagon-like peptide 1 — incretin, satiety, blood sugar, semaglutide's mechanism.